Richard A. Van Etten

Director, Chao Family Comprehensive Cancer Center

Professor, Division of Hematology/Oncology, Medicine
School of Medicine

M.D., Stanford University School of Medicine, 1984


Ph.D., Stanford University, 1984, Biophysics

Phone: (949) 824-2655
Email: vanetten@uci.edu

University of California, Irvine
839 Medical Science Court
Sprague Hall, Room 124
Irvine, CA 92697

picture of Richard A. Van Etten

   
Publications Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. New Engl. J. Med. 2005; 353:172-187.
   
  Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 2007; 7:332-344.
   
  Chan WW, Wise SC, Kaufman MD, Ahn Y-M, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP, Miller D, Patt WC, Smith BD, Petillo PA, Rutkoski TJ, Telikepalli H, Vogeti L, Yao T, Chun L, Clark R, Evangelista P, Gavrilescu LC, Lazarides K, Zaleskas VM, Stewart L, Van Etten RA, Flynn DL. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011; 19:556-568. PMC3077923
   
  Okimoto RA, Van Etten RA. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr. Opin. Hematol. 2011; 18:89-97. PMC3496274
   
  Lu Y-F, Betancur M, Lazarides K, Klingemann H, Van Etten RA. Distinct graft-vs-leukemic stem cell effect of early or delayed donor leukocyte infusion in a mouse chronic myeloid leukemia model. Blood 2012; 119:273-284. PMC3251232
   
  Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, Zaleskas VM, Van Etten RA. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F. Blood 2012; 119(15):3550-3560. PMC3325042
   
  Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H, Ailawadhi S, Akard L, Baer M, Baccarani M, Emmons R, Etienne G, Guerci A, Guilhot F, Hellmann A, Huguet-Rigal F, Khoury H, Laneuville P, Coutre PL, Legros L, Leitner A, Maloisel F, Marin D, Masszi T, Parikh P, Rivera C, Rousselot P, Facon T, Van Etten R, Warzocha K,Wetzler M, Wiernik P. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012;120(13):2573-2580.
   
  Ahmed W, Van Etten RA. Alternative approaches to eradicating the malignant clone in CML: TKI combinations and beyond. Hematology Am Soc Hematol Educ Program 2013;2013:189-200.
   
  Mughal TI, Girnius S, Rosen S, Kumar S, Weistner A, Abdel-Wahab O, Kiladjian J-J, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the deregulated JAK/STATpathways in hematologic malignancies. Leuk. Lymphoma 2013; Epub Nov 11. doi:10.3109/10428194.2013.863307.
   
  Ahmed W, Van Etten RA. Signal transduction in the chronic leukemias: Implications for targeted therapies. Curr. Hematol. Malig. Rep. 2013;8(1):71-80. NIHMSID 434916
   
  Kantarjian H, et al. The price of drugs for chronic myeloid leukemia (CML); A reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 2013; 121:4439-4442.
   
  Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein A, Sprague K, Miller K, Comenzo R, Kewalramani T, Yu N, Van Etten RA, McKenna D. Autologous stem celltransplant recipients tolerate haploidentical related-donor natural killer cell enriched infusions. Transfusion 2013;53(2):412-418. NIHMS378771
   
  Mughal TI, Girnius S, Rosen S, Kumar S, Weistner A, Abdel-Wahab O, Kiladjian J-J, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the deregulated JAK/STAT pathways in hematologic malignancies. Leuk. Lymphoma 2013; Epub Nov 11. doi:10.3109/10428194.2013.863307.
   
  Ahmed W, Van Etten RA. Signal transduction in the chronic leukemias: Implications for targeted therapies. Curr. Hematol. Malig. Rep. 2013;8(1):71-80. NIHMSID 434916
   
  Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D,Hurley MP, Lezeau S, Attar EC, Wu JW, Lin HY, Divieti-Pajevic P, Hasserjian RP, Schipani E, Van Etten RA, Scadden DT. Differential regulation of myeloid leukemia by the bone marrow microenvironment. Nature Medicine 2013;19:1513-1517.
   
  Krause DS, Lazarides K, Lewis JB, von Andrian UH, Van Etten RA. Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemia-initiating cells. Blood 2014; Epub Jan 6. doi: 10.1182/blood-2013-11-538694.
   
  Hsieh M-Y, Van Etten RA. IKK-dependent activation of NF-?B contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. Blood 2014; Epub Jan 24. doi: 10.1182/blood-2014-01-547943.
   
  Joshi I, Yoshida T, Jena N, Qi X, Zhang J, Van Etten RA, Georgopoulos K. Loss of Ikaros DNA-binding function confers integrin-dependent survival of pre-B cells and progression to acute lymphoblastic leukemia. Nature Immunology 2014; in press. NIHMSID 550805
   
Professional
Societies
American Associate for Advancement of Science
American Society of Hematology
American Society of Clinical Oncology
Member, Eastern Cooperative Oncology Group, Leukemia Comm.
Contributing Editor, UpToDate
Editorial Board, Journal of Clinical Oncology
   
   
Link to this profile http://www.faculty.uci.edu/profile.cfm?faculty_id=6033
   
Last updated 01/30/2014